On July 9, Merck announced that it would acquire Verona Pharma, a U.K.-based biotechnology company specializing in the ...

Merck & Company, Inc. (NYSE:MRK) is one of the high-margin pharma stocks to buy now. Jefferies has raised its price target on ...

For $10 billion, Merck is acquiring a promising healthcare company which is in the early stages of its growth. Key to its ...

Merck is making big pharma waves again with a $10 billion deal to acquire Verona Pharma, reports Colin Kellaher for the Wall ...

The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...

A key patent for Merck’s blockbuster drug Keytruda will expire in 2028. The cancer therapy brought the company $29.5 billion ...

Charles E. Hamner Jr., a highly respected and accomplished scientist, university administrator and pharmaceutical executive who led the North Carolina Biotechnology Center during its formative years, ...

Verona Pharma, a year after receiving regulatory approval for its landmark chronic obstructive pulmonary disease (COPD) treatment, is being acquired by pharmaceutical giant Merck in a deal worth about ...

Verona Pharma plc (NASDAQ:VRNA) is one of the 10 Stocks Going Wild. Verona Pharma surged by 20.62 percent on Wednesday to end ...

Freshfields and Latham & Watkins are advising on the latest pharmaceutical mega-deal as U.S. pharmaceutical group Merck snaps ...